Clinical trial · no report yet · Phase 3
KEYNOTE-B15
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
- NCT04700124 ↗
- Active not recruiting
- Merck Sharp & Dohme LLC
- 230 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 111 | |
| YouTube | 68 | |
| Podcasts | 46 | |
| X videos | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Bladder Cancer
- Interventions
- Pembrolizumab; Enfortumab vedotin (EV); RC + PLND; Gemcitabine; Cisplatin
- Arms
- Arm A: Perioperative EV+ Pembrolizumab and RC + PLND · Experimental
- Arm B: Standard of Care (SOC)-Neoadjuvant chemotherapy (gemcitabine + cisplatin) and RC + PLND · Active comparator
- Enrollment
- 808
- Primary outcomes
- Event-Free Survival (EFS)
- Sponsor
- Merck Sharp & Dohme LLC with Seagen Inc., Astellas Pharma Inc
- Start
- Apr 21, 2021
- Primary completion
- Oct 27, 2025
- Results posted
- No
- Registry record
- NCT04700124 · updated Jul 16, 2026
Publications
linked from the registry- Galsky MD, Valderrama BP, Maruzzo M, Font A, Ciuleanu T, Chatzkel J, Koie T, Hoimes CJ, Puente J, Zakharia Y, Rosenbaum E, Boehm K, Loriot Y, Bedke J, Powles TB, Necchi A, Wiechno P, Alvarez-Fernandez C, Kim TH, Oliveira N, Flaig TW, Wirtz HS, Mihm M, Huang Q, Rogiers A, Homet Moreno B, Gomez de Liano A; KEYNOTE-B15/EV-304 Investigators. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. N Engl J Med. 2026 Jul 23;395(4):338-348. doi: 10.1056/NEJMoa2601486. PubMed 42485627